Drug intelligence / Profile preview

PBI-1393

Development stage: Unknown
Lead developer: Liminal BioSciences
Modality: Small Molecules

Overview

PBI-1393 (also known as BCH-1393) is a small molecule immunomodulator designed to enhance Th1-type immune responses. Chemically identified as N,N-Dimethylaminopurine pentoxycarbonyl D-arginine, it acts by promoting the production of Th1-type cytokines, such as interferon-gamma (IFN-γ) and interleukin-2 (IL-2), and facilitating primary T-cell activation. Originally developed by BioChem Pharma and later associated with ProMetic BioSciences, the compound was investigated for its potential in immunotherapy, particularly for bolstering cellular immunity in the context of oncology and infectious diseases. It remains a research-stage compound and has not reached clinical approval.

Other names: N,N-Dimethylaminopurine pentoxycarbonyl D-arginine

Targets

IL-2 (Interleukin 2)IFNG (Interferon gamma)

Beyond the preview

Go deeper on PBI-1393.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBI-1393.

Explore the full profile